Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C36H42O2P.Br |
| Molecular Weight | 617.595 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].CC1=C(C)C(=O)C(CCCCCCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)=CC1=O
InChI
InChIKey=WYHFWTRUGAFNKW-UHFFFAOYSA-M
InChI=1S/C36H42O2P.BrH/c1-29-30(2)36(38)31(28-35(29)37)20-12-7-5-3-4-6-8-19-27-39(32-21-13-9-14-22-32,33-23-15-10-16-24-33)34-25-17-11-18-26-34;/h9-11,13-18,21-26,28H,3-8,12,19-20,27H2,1-2H3;1H/q+1;/p-1
| Molecular Formula | BrH |
| Molecular Weight | 80.912 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C36H42O2P |
| Molecular Weight | 537.6912 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:30:09 GMT 2025
by
admin
on
Tue Apr 01 16:30:09 GMT 2025
|
| Record UNII |
7B14500J3E
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
846221
Created by
admin on Tue Apr 01 16:30:09 GMT 2025 , Edited by admin on Tue Apr 01 16:30:09 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
934826-68-3
Created by
admin on Tue Apr 01 16:30:09 GMT 2025 , Edited by admin on Tue Apr 01 16:30:09 GMT 2025
|
PRIMARY | |||
|
7B14500J3E
Created by
admin on Tue Apr 01 16:30:09 GMT 2025 , Edited by admin on Tue Apr 01 16:30:09 GMT 2025
|
PRIMARY | |||
|
300000040779
Created by
admin on Tue Apr 01 16:30:09 GMT 2025 , Edited by admin on Tue Apr 01 16:30:09 GMT 2025
|
PRIMARY | |||
|
16679091
Created by
admin on Tue Apr 01 16:30:09 GMT 2025 , Edited by admin on Tue Apr 01 16:30:09 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Due to highly targeted delivery of SkQ1 to mitochondria and its potency as antioxidant, topical application of SkQ1-based formulations proved to be very effective in treating several eye pathologies in animal models and in humans. More than a dozen studies have been conducted and showed SkQ1 effectiveness in such critical therapeutic areas as the following: Age-related macular degeneration (AMD), Dry eye syndrome (DES), Non-infectious uveitis, Cataracts and Glaucoma.
|
||
|
ACTIVE MOIETY |
In the second series, the illuminated rats were treated for two weeks with Visomitin or similar drops without SkQ1. The damaged retinas of the experimental animals were repaired much more effectively than those of the control animals. Therefore, we conclude that Visomitin SkQ1-containing eye drops have pronounced preventive and therapeutic effects on the photodamaged retina and might be recommended as a photoprotector and a pharmaceutical preparation for the treatment of AMD in combination with conventional medicines.
|